Calamos Advisors
CYTK icon

Calamos Advisors’s Cytokinetics CYTK Stock Holding History

Calamos Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38M Buy
51,443
+29,816
+138% +$2.14M 0.01% 567
2026
Q1 		$1.43M Buy
+21,627
New +$1.37M 0.01% 723
2022
Q4 		– Sell
-91,204
Closed -$4.42M – 1256
2022
Q3 		$4.42M Buy
91,204
+13,181
+17% +$634K 0.02% 735
2022
Q2 		$3.07M Buy
+78,023
New +$3.14M 0.01% 830

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Calamos Advisors's CYTK Position: Q2 2026 in Review

Calamos Advisors increased its Cytokinetics (CYTK) stake by 138% in Q2 2026, buying an estimated $2.14M and bringing the position to 51,443 shares worth $4.38M. The position accounts for 0.01% of the portfolio, ranked #567.

Calamos Advisors first reported a position in CYTK in Q2 2022 and has held it in 4 quarters since. The position peaked at $4.42M in Q3 2022. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Calamos Advisors held 51,443 shares of Cytokinetics worth $4.38M as of Q2 2026.
  • Calamos Advisors bought 29,816 Cytokinetics shares in Q2 2026, an estimated $2.14M.
  • Cytokinetics made up 0.01% of Calamos Advisors's portfolio in Q2 2026, its #567 holding.
  • Calamos Advisors first reported a position in Cytokinetics in Q2 2022 and has held it in 4 quarters since.
  • Calamos Advisors's Cytokinetics position peaked at $4.42M in Q3 2022.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.